Glossary · Conditions

Chemical menopause

Also called: Induced menopause.

Definition: Chemical menopause, also called induced menopause, is iatrogenic loss of ovarian function from chemotherapy, pelvic radiation, or GnRH agonist therapy (e.g., leuprolide). It can be temporary or permanent depending on the agent, dose, and the patient's age and ovarian reserve. Symptoms can be as severe as surgical menopause.

Detailed definition

Chemical menopause refers to ovarian suppression or failure caused by medical treatments rather than surgery. The three main causes are: cytotoxic chemotherapy (alkylating agents like cyclophosphamide are most damaging), pelvic radiation (depending on dose and ovarian shielding), and GnRH agonist or antagonist therapy (used for breast cancer, endometriosis, fibroids). GnRH-induced menopause is reversible — ovarian function typically resumes within 6–12 months of stopping the drug. Chemotherapy-induced menopause varies: younger women with high ovarian reserve may resume cycles after treatment, while older women or those receiving high-dose alkylating regimens often have permanent loss. Symptoms during chemical menopause are typically as severe as surgical menopause and include vasomotor symptoms, sleep disruption, mood changes, and GSM. Whether HRT is appropriate depends heavily on the underlying disease — it is generally contraindicated in hormone-sensitive cancer treatment (breast, some uterine), but may be used for non-hormonal indications.

Why it matters in menopause

For women going through chemotherapy or on GnRH agonists, menopausal symptoms are often severe and undertreated. Non-hormonal options — fezolinetant, low-dose paroxetine, gabapentin, vaginal moisturizers, vaginal DHEA — become important. For women with non-hormone-sensitive disease, full HRT is sometimes appropriate after oncology consultation.

Sources

External references: Wikipedia.

← Back to full glossary